Global HIV-AIDS Diagnostics Market

HIV-AIDS Diagnostics Comprehensive Study by Type (Assay, Kit, Reagent, Instrument, Software, Services, Others), Application (Diagnostic Laboratories, Hospitals, Blood Banks, Home Care Settings, Other), Test Type (Antibody Tests (ELISA) Players and Region - Global Market Outlook to 2030

HIV-AIDS Diagnostics Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About HIV-AIDS Diagnostics
According to WHO study, HIV-AIDS is the major health concern among the public, with an increased prevalence rate of HIV and subsequent increase of patients suffering from HIV-AIDS has tremendous demand for technologies for HIV-ADIS diagnostics among people. HIV is Human Immunodeficiency Virus that causes an infection that leads to Acquired Immunodeficiency Syndrome (AIDS) and hence leads to a weak immune system and allows life-threatening infections and cancer to thrive in, it often spread through unprotected sex with an infected person or sharing needles with an infected person, and infected blood transfusions. HIV-AIDS diagnostics help in initial detection and enhanced treatment along with effective patient care, which prevents health degradation and helps in retaining one’s quality of life.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global HIV-AIDS Diagnostics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Siemens AG (Germany), Roche Diagnostics (Switzerland), Abbott Laboratories (United States), Danaher Corporation (United States), Thermo-Fisher Scientific Inc. (United States), Merck KGaA (Germany), Becton, Dickinson, and Company (United States), Hologic, Inc. (United States), Alere Inc. (United States) and Bio-Rad Laboratories (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global HIV-AIDS Diagnostics market by Type (Assay, Kit, Reagent, Instrument, Software, Services and Others), Application (Diagnostic Laboratories, Hospitals, Blood Banks, Home Care Settings and Other) and Region.



On the basis of geography, the market of HIV-AIDS Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Test Type, the sub-segment i.e. Antibody Tests (ELISA will boost the HIV-AIDS Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Adoption of Use of Home Access Kits and Instruments

Market Growth Drivers:
Growing Worldwide Occurrence of HIV/Aids, Increasing Number of Blood Transfusions and Blood Donations Globally and Increasing Government Initiatives for HIV-ADIS Free Population

Challenges:
Issue Related to Cost and Limited Centralized Testing Facilities and Rapid Molecular Change for HIV Diagnostics

Restraints:
High Cost of Nat (Nucleic Acid Tests) and Lack of Mandates for Nat in Developing Countries

Opportunities:
Growth Opportunities for HIV Diagnosis in Emerging Economies and Rising Research and Development for Early Diagnosis, Treatment, and Prevention Form HIV-AIDS

Market Leaders and their expansionary development strategies
In September 2020, Roche , launched of the Elecsys HIV Duo immunoassay in the U.S., following FDA approved. Through separate measurement of the HIV p24 antigen (the virus) and anti-HIV antibodies (caused by immune reaction), this test can detect an acute HIV infection earlier than current methods. This approval enables a robust, comprehensive infectious diseases menu on the cobas e 801 system and a significant step towards bringing holistic value to the U.S. market within the area of infectious diseases.
In August 2022, Molbio Diagnostics has launched a new test for differential diagnosis of HIV 1 and HIV 2 with viral loads within 60 minutes. The test works on the existing Truelab infrastructure and will require no additional set-ups and equipment, the company claims.


Key Target Audience
Manufacturers of HIV Diagnosis Products, Vendors and Distributors of Powered Surgical Instruments, Hospitals, Research Institutes Related to HIV/AIDS Studies, Venture Capitalists and Investors and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Assay
  • Kit
  • Reagent
  • Instrument
  • Software
  • Services
  • Others
By Application
  • Diagnostic Laboratories
  • Hospitals
  • Blood Banks
  • Home Care Settings
  • Other
By Test Type
  • Antibody Tests (ELISA

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Worldwide Occurrence of HIV/Aids
      • 3.2.2. Increasing Number of Blood Transfusions and Blood Donations Globally
      • 3.2.3. Increasing Government Initiatives for HIV-ADIS Free Population
    • 3.3. Market Challenges
      • 3.3.1. Issue Related to Cost and Limited Centralized Testing Facilities
      • 3.3.2. Rapid Molecular Change for HIV Diagnostics
    • 3.4. Market Trends
      • 3.4.1. Adoption of Use of Home Access Kits and Instruments
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global HIV-AIDS Diagnostics, by Type, Application, Test Type and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global HIV-AIDS Diagnostics (Value)
      • 5.2.1. Global HIV-AIDS Diagnostics by: Type (Value)
        • 5.2.1.1. Assay
        • 5.2.1.2. Kit
        • 5.2.1.3. Reagent
        • 5.2.1.4. Instrument
        • 5.2.1.5. Software
        • 5.2.1.6. Services
        • 5.2.1.7. Others
      • 5.2.2. Global HIV-AIDS Diagnostics by: Application (Value)
        • 5.2.2.1. Diagnostic Laboratories
        • 5.2.2.2. Hospitals
        • 5.2.2.3. Blood Banks
        • 5.2.2.4. Home Care Settings
        • 5.2.2.5. Other
      • 5.2.3. Global HIV-AIDS Diagnostics by: Test Type (Value)
        • 5.2.3.1. Antibody Tests (ELISA
      • 5.2.4. Global HIV-AIDS Diagnostics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global HIV-AIDS Diagnostics (Volume)
      • 5.3.1. Global HIV-AIDS Diagnostics by: Type (Volume)
        • 5.3.1.1. Assay
        • 5.3.1.2. Kit
        • 5.3.1.3. Reagent
        • 5.3.1.4. Instrument
        • 5.3.1.5. Software
        • 5.3.1.6. Services
        • 5.3.1.7. Others
      • 5.3.2. Global HIV-AIDS Diagnostics by: Application (Volume)
        • 5.3.2.1. Diagnostic Laboratories
        • 5.3.2.2. Hospitals
        • 5.3.2.3. Blood Banks
        • 5.3.2.4. Home Care Settings
        • 5.3.2.5. Other
      • 5.3.3. Global HIV-AIDS Diagnostics by: Test Type (Volume)
        • 5.3.3.1. Antibody Tests (ELISA
      • 5.3.4. Global HIV-AIDS Diagnostics Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global HIV-AIDS Diagnostics (Price)
      • 5.4.1. Global HIV-AIDS Diagnostics by: Type (Price)
  • 6. HIV-AIDS Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Siemens AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Roche Diagnostics (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abbott Laboratories (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Danaher Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Thermo-Fisher Scientific Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck KGaA (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Becton, Dickinson, and Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hologic, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Alere Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bio-Rad Laboratories (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global HIV-AIDS Diagnostics Sale, by Type, Application, Test Type and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global HIV-AIDS Diagnostics (Value)
      • 7.2.1. Global HIV-AIDS Diagnostics by: Type (Value)
        • 7.2.1.1. Assay
        • 7.2.1.2. Kit
        • 7.2.1.3. Reagent
        • 7.2.1.4. Instrument
        • 7.2.1.5. Software
        • 7.2.1.6. Services
        • 7.2.1.7. Others
      • 7.2.2. Global HIV-AIDS Diagnostics by: Application (Value)
        • 7.2.2.1. Diagnostic Laboratories
        • 7.2.2.2. Hospitals
        • 7.2.2.3. Blood Banks
        • 7.2.2.4. Home Care Settings
        • 7.2.2.5. Other
      • 7.2.3. Global HIV-AIDS Diagnostics by: Test Type (Value)
        • 7.2.3.1. Antibody Tests (ELISA
      • 7.2.4. Global HIV-AIDS Diagnostics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global HIV-AIDS Diagnostics (Volume)
      • 7.3.1. Global HIV-AIDS Diagnostics by: Type (Volume)
        • 7.3.1.1. Assay
        • 7.3.1.2. Kit
        • 7.3.1.3. Reagent
        • 7.3.1.4. Instrument
        • 7.3.1.5. Software
        • 7.3.1.6. Services
        • 7.3.1.7. Others
      • 7.3.2. Global HIV-AIDS Diagnostics by: Application (Volume)
        • 7.3.2.1. Diagnostic Laboratories
        • 7.3.2.2. Hospitals
        • 7.3.2.3. Blood Banks
        • 7.3.2.4. Home Care Settings
        • 7.3.2.5. Other
      • 7.3.3. Global HIV-AIDS Diagnostics by: Test Type (Volume)
        • 7.3.3.1. Antibody Tests (ELISA
      • 7.3.4. Global HIV-AIDS Diagnostics Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global HIV-AIDS Diagnostics (Price)
      • 7.4.1. Global HIV-AIDS Diagnostics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. HIV-AIDS Diagnostics: by Type(USD Million)
  • Table 2. HIV-AIDS Diagnostics Assay , by Region USD Million (2018-2023)
  • Table 3. HIV-AIDS Diagnostics Kit , by Region USD Million (2018-2023)
  • Table 4. HIV-AIDS Diagnostics Reagent , by Region USD Million (2018-2023)
  • Table 5. HIV-AIDS Diagnostics Instrument , by Region USD Million (2018-2023)
  • Table 6. HIV-AIDS Diagnostics Software , by Region USD Million (2018-2023)
  • Table 7. HIV-AIDS Diagnostics Services , by Region USD Million (2018-2023)
  • Table 8. HIV-AIDS Diagnostics Others , by Region USD Million (2018-2023)
  • Table 9. HIV-AIDS Diagnostics: by Application(USD Million)
  • Table 10. HIV-AIDS Diagnostics Diagnostic Laboratories , by Region USD Million (2018-2023)
  • Table 11. HIV-AIDS Diagnostics Hospitals , by Region USD Million (2018-2023)
  • Table 12. HIV-AIDS Diagnostics Blood Banks , by Region USD Million (2018-2023)
  • Table 13. HIV-AIDS Diagnostics Home Care Settings , by Region USD Million (2018-2023)
  • Table 14. HIV-AIDS Diagnostics Other , by Region USD Million (2018-2023)
  • Table 15. HIV-AIDS Diagnostics: by Test Type(USD Million)
  • Table 16. HIV-AIDS Diagnostics Antibody Tests (ELISA , by Region USD Million (2018-2023)
  • Table 17. South America HIV-AIDS Diagnostics, by Country USD Million (2018-2023)
  • Table 18. South America HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 19. South America HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 20. South America HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 21. Brazil HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 22. Brazil HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 23. Brazil HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 24. Argentina HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 25. Argentina HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 26. Argentina HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 27. Rest of South America HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 28. Rest of South America HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 29. Rest of South America HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 30. Asia Pacific HIV-AIDS Diagnostics, by Country USD Million (2018-2023)
  • Table 31. Asia Pacific HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 32. Asia Pacific HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 33. Asia Pacific HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 34. China HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 35. China HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 36. China HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 37. Japan HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 38. Japan HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 39. Japan HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 40. India HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 41. India HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 42. India HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 43. South Korea HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 44. South Korea HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 45. South Korea HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 46. Taiwan HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 47. Taiwan HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 48. Taiwan HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 49. Australia HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 50. Australia HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 51. Australia HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 54. Rest of Asia-Pacific HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 55. Europe HIV-AIDS Diagnostics, by Country USD Million (2018-2023)
  • Table 56. Europe HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 57. Europe HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 58. Europe HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 59. Germany HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 60. Germany HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 61. Germany HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 62. France HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 63. France HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 64. France HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 65. Italy HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 66. Italy HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 67. Italy HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 68. United Kingdom HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 69. United Kingdom HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 70. United Kingdom HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 71. Netherlands HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 72. Netherlands HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 73. Netherlands HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 74. Rest of Europe HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 75. Rest of Europe HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 76. Rest of Europe HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 77. MEA HIV-AIDS Diagnostics, by Country USD Million (2018-2023)
  • Table 78. MEA HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 79. MEA HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 80. MEA HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 81. Middle East HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 82. Middle East HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 83. Middle East HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 84. Africa HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 85. Africa HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 86. Africa HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 87. North America HIV-AIDS Diagnostics, by Country USD Million (2018-2023)
  • Table 88. North America HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 89. North America HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 90. North America HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 91. United States HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 92. United States HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 93. United States HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 94. Canada HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 95. Canada HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 96. Canada HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 97. Mexico HIV-AIDS Diagnostics, by Type USD Million (2018-2023)
  • Table 98. Mexico HIV-AIDS Diagnostics, by Application USD Million (2018-2023)
  • Table 99. Mexico HIV-AIDS Diagnostics, by Test Type USD Million (2018-2023)
  • Table 100. HIV-AIDS Diagnostics Sales: by Type(Unit)
  • Table 101. HIV-AIDS Diagnostics Sales Assay , by Region Unit (2018-2023)
  • Table 102. HIV-AIDS Diagnostics Sales Kit , by Region Unit (2018-2023)
  • Table 103. HIV-AIDS Diagnostics Sales Reagent , by Region Unit (2018-2023)
  • Table 104. HIV-AIDS Diagnostics Sales Instrument , by Region Unit (2018-2023)
  • Table 105. HIV-AIDS Diagnostics Sales Software , by Region Unit (2018-2023)
  • Table 106. HIV-AIDS Diagnostics Sales Services , by Region Unit (2018-2023)
  • Table 107. HIV-AIDS Diagnostics Sales Others , by Region Unit (2018-2023)
  • Table 108. HIV-AIDS Diagnostics Sales: by Application(Unit)
  • Table 109. HIV-AIDS Diagnostics Sales Diagnostic Laboratories , by Region Unit (2018-2023)
  • Table 110. HIV-AIDS Diagnostics Sales Hospitals , by Region Unit (2018-2023)
  • Table 111. HIV-AIDS Diagnostics Sales Blood Banks , by Region Unit (2018-2023)
  • Table 112. HIV-AIDS Diagnostics Sales Home Care Settings , by Region Unit (2018-2023)
  • Table 113. HIV-AIDS Diagnostics Sales Other , by Region Unit (2018-2023)
  • Table 114. HIV-AIDS Diagnostics Sales: by Test Type(Unit)
  • Table 115. HIV-AIDS Diagnostics Sales Antibody Tests (ELISA , by Region Unit (2018-2023)
  • Table 116. South America HIV-AIDS Diagnostics Sales, by Country Unit (2018-2023)
  • Table 117. South America HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 118. South America HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 119. South America HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 120. Brazil HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 121. Brazil HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 122. Brazil HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 123. Argentina HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 124. Argentina HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 125. Argentina HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 126. Rest of South America HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 127. Rest of South America HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 128. Rest of South America HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 129. Asia Pacific HIV-AIDS Diagnostics Sales, by Country Unit (2018-2023)
  • Table 130. Asia Pacific HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 131. Asia Pacific HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 132. Asia Pacific HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 133. China HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 134. China HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 135. China HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 136. Japan HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 137. Japan HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 138. Japan HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 139. India HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 140. India HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 141. India HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 142. South Korea HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 143. South Korea HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 144. South Korea HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 145. Taiwan HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 146. Taiwan HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 147. Taiwan HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 148. Australia HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 149. Australia HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 150. Australia HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 151. Rest of Asia-Pacific HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 152. Rest of Asia-Pacific HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 153. Rest of Asia-Pacific HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 154. Europe HIV-AIDS Diagnostics Sales, by Country Unit (2018-2023)
  • Table 155. Europe HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 156. Europe HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 157. Europe HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 158. Germany HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 159. Germany HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 160. Germany HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 161. France HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 162. France HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 163. France HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 164. Italy HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 165. Italy HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 166. Italy HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 167. United Kingdom HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 168. United Kingdom HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 169. United Kingdom HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 170. Netherlands HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 171. Netherlands HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 172. Netherlands HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 173. Rest of Europe HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 174. Rest of Europe HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 175. Rest of Europe HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 176. MEA HIV-AIDS Diagnostics Sales, by Country Unit (2018-2023)
  • Table 177. MEA HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 178. MEA HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 179. MEA HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 180. Middle East HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 181. Middle East HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 182. Middle East HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 183. Africa HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 184. Africa HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 185. Africa HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 186. North America HIV-AIDS Diagnostics Sales, by Country Unit (2018-2023)
  • Table 187. North America HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 188. North America HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 189. North America HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 190. United States HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 191. United States HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 192. United States HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 193. Canada HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 194. Canada HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 195. Canada HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 196. Mexico HIV-AIDS Diagnostics Sales, by Type Unit (2018-2023)
  • Table 197. Mexico HIV-AIDS Diagnostics Sales, by Application Unit (2018-2023)
  • Table 198. Mexico HIV-AIDS Diagnostics Sales, by Test Type Unit (2018-2023)
  • Table 199. HIV-AIDS Diagnostics: by Type(USD/Units)
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. HIV-AIDS Diagnostics: by Type(USD Million)
  • Table 211. HIV-AIDS Diagnostics Assay , by Region USD Million (2025-2030)
  • Table 212. HIV-AIDS Diagnostics Kit , by Region USD Million (2025-2030)
  • Table 213. HIV-AIDS Diagnostics Reagent , by Region USD Million (2025-2030)
  • Table 214. HIV-AIDS Diagnostics Instrument , by Region USD Million (2025-2030)
  • Table 215. HIV-AIDS Diagnostics Software , by Region USD Million (2025-2030)
  • Table 216. HIV-AIDS Diagnostics Services , by Region USD Million (2025-2030)
  • Table 217. HIV-AIDS Diagnostics Others , by Region USD Million (2025-2030)
  • Table 218. HIV-AIDS Diagnostics: by Application(USD Million)
  • Table 219. HIV-AIDS Diagnostics Diagnostic Laboratories , by Region USD Million (2025-2030)
  • Table 220. HIV-AIDS Diagnostics Hospitals , by Region USD Million (2025-2030)
  • Table 221. HIV-AIDS Diagnostics Blood Banks , by Region USD Million (2025-2030)
  • Table 222. HIV-AIDS Diagnostics Home Care Settings , by Region USD Million (2025-2030)
  • Table 223. HIV-AIDS Diagnostics Other , by Region USD Million (2025-2030)
  • Table 224. HIV-AIDS Diagnostics: by Test Type(USD Million)
  • Table 225. HIV-AIDS Diagnostics Antibody Tests (ELISA , by Region USD Million (2025-2030)
  • Table 226. South America HIV-AIDS Diagnostics, by Country USD Million (2025-2030)
  • Table 227. South America HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 228. South America HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 229. South America HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 230. Brazil HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 231. Brazil HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 232. Brazil HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 233. Argentina HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 234. Argentina HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 235. Argentina HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 236. Rest of South America HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 237. Rest of South America HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 238. Rest of South America HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 239. Asia Pacific HIV-AIDS Diagnostics, by Country USD Million (2025-2030)
  • Table 240. Asia Pacific HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 241. Asia Pacific HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 242. Asia Pacific HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 243. China HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 244. China HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 245. China HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 246. Japan HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 247. Japan HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 248. Japan HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 249. India HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 250. India HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 251. India HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 252. South Korea HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 253. South Korea HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 254. South Korea HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 255. Taiwan HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 256. Taiwan HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 257. Taiwan HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 258. Australia HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 259. Australia HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 260. Australia HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 261. Rest of Asia-Pacific HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 262. Rest of Asia-Pacific HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 263. Rest of Asia-Pacific HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 264. Europe HIV-AIDS Diagnostics, by Country USD Million (2025-2030)
  • Table 265. Europe HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 266. Europe HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 267. Europe HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 268. Germany HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 269. Germany HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 270. Germany HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 271. France HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 272. France HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 273. France HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 274. Italy HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 275. Italy HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 276. Italy HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 277. United Kingdom HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 278. United Kingdom HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 279. United Kingdom HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 280. Netherlands HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 281. Netherlands HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 282. Netherlands HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 283. Rest of Europe HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 284. Rest of Europe HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 285. Rest of Europe HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 286. MEA HIV-AIDS Diagnostics, by Country USD Million (2025-2030)
  • Table 287. MEA HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 288. MEA HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 289. MEA HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 290. Middle East HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 291. Middle East HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 292. Middle East HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 293. Africa HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 294. Africa HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 295. Africa HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 296. North America HIV-AIDS Diagnostics, by Country USD Million (2025-2030)
  • Table 297. North America HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 298. North America HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 299. North America HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 300. United States HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 301. United States HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 302. United States HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 303. Canada HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 304. Canada HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 305. Canada HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 306. Mexico HIV-AIDS Diagnostics, by Type USD Million (2025-2030)
  • Table 307. Mexico HIV-AIDS Diagnostics, by Application USD Million (2025-2030)
  • Table 308. Mexico HIV-AIDS Diagnostics, by Test Type USD Million (2025-2030)
  • Table 309. HIV-AIDS Diagnostics Sales: by Type(Unit)
  • Table 310. HIV-AIDS Diagnostics Sales Assay , by Region Unit (2025-2030)
  • Table 311. HIV-AIDS Diagnostics Sales Kit , by Region Unit (2025-2030)
  • Table 312. HIV-AIDS Diagnostics Sales Reagent , by Region Unit (2025-2030)
  • Table 313. HIV-AIDS Diagnostics Sales Instrument , by Region Unit (2025-2030)
  • Table 314. HIV-AIDS Diagnostics Sales Software , by Region Unit (2025-2030)
  • Table 315. HIV-AIDS Diagnostics Sales Services , by Region Unit (2025-2030)
  • Table 316. HIV-AIDS Diagnostics Sales Others , by Region Unit (2025-2030)
  • Table 317. HIV-AIDS Diagnostics Sales: by Application(Unit)
  • Table 318. HIV-AIDS Diagnostics Sales Diagnostic Laboratories , by Region Unit (2025-2030)
  • Table 319. HIV-AIDS Diagnostics Sales Hospitals , by Region Unit (2025-2030)
  • Table 320. HIV-AIDS Diagnostics Sales Blood Banks , by Region Unit (2025-2030)
  • Table 321. HIV-AIDS Diagnostics Sales Home Care Settings , by Region Unit (2025-2030)
  • Table 322. HIV-AIDS Diagnostics Sales Other , by Region Unit (2025-2030)
  • Table 323. HIV-AIDS Diagnostics Sales: by Test Type(Unit)
  • Table 324. HIV-AIDS Diagnostics Sales Antibody Tests (ELISA , by Region Unit (2025-2030)
  • Table 325. South America HIV-AIDS Diagnostics Sales, by Country Unit (2025-2030)
  • Table 326. South America HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 327. South America HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 328. South America HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 329. Brazil HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 330. Brazil HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 331. Brazil HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 332. Argentina HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 333. Argentina HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 334. Argentina HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 335. Rest of South America HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 336. Rest of South America HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 337. Rest of South America HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 338. Asia Pacific HIV-AIDS Diagnostics Sales, by Country Unit (2025-2030)
  • Table 339. Asia Pacific HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 340. Asia Pacific HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 341. Asia Pacific HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 342. China HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 343. China HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 344. China HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 345. Japan HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 346. Japan HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 347. Japan HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 348. India HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 349. India HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 350. India HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 351. South Korea HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 352. South Korea HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 353. South Korea HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 354. Taiwan HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 355. Taiwan HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 356. Taiwan HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 357. Australia HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 358. Australia HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 359. Australia HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 360. Rest of Asia-Pacific HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 361. Rest of Asia-Pacific HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 362. Rest of Asia-Pacific HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 363. Europe HIV-AIDS Diagnostics Sales, by Country Unit (2025-2030)
  • Table 364. Europe HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 365. Europe HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 366. Europe HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 367. Germany HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 368. Germany HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 369. Germany HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 370. France HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 371. France HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 372. France HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 373. Italy HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 374. Italy HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 375. Italy HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 376. United Kingdom HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 377. United Kingdom HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 378. United Kingdom HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 379. Netherlands HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 380. Netherlands HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 381. Netherlands HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 382. Rest of Europe HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 383. Rest of Europe HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 384. Rest of Europe HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 385. MEA HIV-AIDS Diagnostics Sales, by Country Unit (2025-2030)
  • Table 386. MEA HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 387. MEA HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 388. MEA HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 389. Middle East HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 390. Middle East HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 391. Middle East HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 392. Africa HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 393. Africa HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 394. Africa HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 395. North America HIV-AIDS Diagnostics Sales, by Country Unit (2025-2030)
  • Table 396. North America HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 397. North America HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 398. North America HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 399. United States HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 400. United States HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 401. United States HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 402. Canada HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 403. Canada HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 404. Canada HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 405. Mexico HIV-AIDS Diagnostics Sales, by Type Unit (2025-2030)
  • Table 406. Mexico HIV-AIDS Diagnostics Sales, by Application Unit (2025-2030)
  • Table 407. Mexico HIV-AIDS Diagnostics Sales, by Test Type Unit (2025-2030)
  • Table 408. HIV-AIDS Diagnostics: by Type(USD/Units)
  • Table 409. Research Programs/Design for This Report
  • Table 410. Key Data Information from Secondary Sources
  • Table 411. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global HIV-AIDS Diagnostics: by Type USD Million (2018-2023)
  • Figure 5. Global HIV-AIDS Diagnostics: by Application USD Million (2018-2023)
  • Figure 6. Global HIV-AIDS Diagnostics: by Test Type USD Million (2018-2023)
  • Figure 7. South America HIV-AIDS Diagnostics Share (%), by Country
  • Figure 8. Asia Pacific HIV-AIDS Diagnostics Share (%), by Country
  • Figure 9. Europe HIV-AIDS Diagnostics Share (%), by Country
  • Figure 10. MEA HIV-AIDS Diagnostics Share (%), by Country
  • Figure 11. North America HIV-AIDS Diagnostics Share (%), by Country
  • Figure 12. Global HIV-AIDS Diagnostics: by Type Unit (2018-2023)
  • Figure 13. Global HIV-AIDS Diagnostics: by Application Unit (2018-2023)
  • Figure 14. Global HIV-AIDS Diagnostics: by Test Type Unit (2018-2023)
  • Figure 15. South America HIV-AIDS Diagnostics Share (%), by Country
  • Figure 16. Asia Pacific HIV-AIDS Diagnostics Share (%), by Country
  • Figure 17. Europe HIV-AIDS Diagnostics Share (%), by Country
  • Figure 18. MEA HIV-AIDS Diagnostics Share (%), by Country
  • Figure 19. North America HIV-AIDS Diagnostics Share (%), by Country
  • Figure 20. Global HIV-AIDS Diagnostics: by Type USD/Units (2018-2023)
  • Figure 21. Global HIV-AIDS Diagnostics share by Players 2023 (%)
  • Figure 22. Global HIV-AIDS Diagnostics share by Players (Top 3) 2023(%)
  • Figure 23. Global HIV-AIDS Diagnostics share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Siemens AG (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Siemens AG (Germany) Revenue: by Geography 2023
  • Figure 27. Roche Diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Roche Diagnostics (Switzerland) Revenue: by Geography 2023
  • Figure 29. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 30. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 31. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 32. Danaher Corporation (United States) Revenue: by Geography 2023
  • Figure 33. Thermo-Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Thermo-Fisher Scientific Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 37. Becton, Dickinson, and Company (United States) Revenue, Net Income and Gross profit
  • Figure 38. Becton, Dickinson, and Company (United States) Revenue: by Geography 2023
  • Figure 39. Hologic, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Hologic, Inc. (United States) Revenue: by Geography 2023
  • Figure 41. Alere Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Alere Inc. (United States) Revenue: by Geography 2023
  • Figure 43. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 44. Bio-Rad Laboratories (United States) Revenue: by Geography 2023
  • Figure 45. Global HIV-AIDS Diagnostics: by Type USD Million (2025-2030)
  • Figure 46. Global HIV-AIDS Diagnostics: by Application USD Million (2025-2030)
  • Figure 47. Global HIV-AIDS Diagnostics: by Test Type USD Million (2025-2030)
  • Figure 48. South America HIV-AIDS Diagnostics Share (%), by Country
  • Figure 49. Asia Pacific HIV-AIDS Diagnostics Share (%), by Country
  • Figure 50. Europe HIV-AIDS Diagnostics Share (%), by Country
  • Figure 51. MEA HIV-AIDS Diagnostics Share (%), by Country
  • Figure 52. North America HIV-AIDS Diagnostics Share (%), by Country
  • Figure 53. Global HIV-AIDS Diagnostics: by Type Unit (2025-2030)
  • Figure 54. Global HIV-AIDS Diagnostics: by Application Unit (2025-2030)
  • Figure 55. Global HIV-AIDS Diagnostics: by Test Type Unit (2025-2030)
  • Figure 56. South America HIV-AIDS Diagnostics Share (%), by Country
  • Figure 57. Asia Pacific HIV-AIDS Diagnostics Share (%), by Country
  • Figure 58. Europe HIV-AIDS Diagnostics Share (%), by Country
  • Figure 59. MEA HIV-AIDS Diagnostics Share (%), by Country
  • Figure 60. North America HIV-AIDS Diagnostics Share (%), by Country
  • Figure 61. Global HIV-AIDS Diagnostics: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Siemens AG (Germany)
  • Roche Diagnostics (Switzerland)
  • Abbott Laboratories (United States)
  • Danaher Corporation (United States)
  • Thermo-Fisher Scientific Inc. (United States)
  • Merck KGaA (Germany)
  • Becton, Dickinson, and Company (United States)
  • Hologic, Inc. (United States)
  • Alere Inc. (United States)
  • Bio-Rad Laboratories (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 156 Pages 61 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global HIV-AIDS Diagnostics Market Quantitative research analysis
Global HIV-AIDS Diagnostics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Siemens AG (Germany), Roche Diagnostics (Switzerland), Abbott Laboratories (United States), Danaher Corporation (United States), Thermo-Fisher Scientific Inc. (United States), Merck KGaA (Germany), Becton, Dickinson, and Company (United States), Hologic, Inc. (United States), Alere Inc. (United States) and Bio-Rad Laboratories (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Adoption of Use of Home Access Kits and Instruments" is seen as one of major influencing trends for HIV-AIDS Diagnostics Market during projected period 2023-2030.
The HIV-AIDS Diagnostics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global HIV-AIDS Diagnostics Market Report?

Have a Query? Click Here

Other Related Reports

Healthcare Contract Research Outsourcing Comprehensive Study by Service (Clinical Trial Service, Regulatory Service, Clinical Data Management & Biometrics, Medical Writing, Site Management Protocol, ...
$ 3750
Private Healthcare Comprehensive Study by Application (Hospitals, Pharmaceutical Industries, Medical Devices, Health Insurance, Medical Devices and Equipment, Others), Services (Curative, Preventive,...
$ 3350
Rickets Treatment Comprehensive Study by Type (Vitamin D-Related Rickets, Minerals Related Rickets), End User (Hospital, Clinics) Players and Region - Global Market Outlook to 2026
$ 3500
Small Joint Replacement Comprehensive Study by Type (Ankle Replacement, Digits Replacement, Elbow Replacement, Wrist Replacement), Application (Hospitals, Orthopedic Centers, Ambulatory Surgery Cente...
$ 3350
Medical Imaging Informatics Comprehensive Study by Type (Digital Radiography, Ultrasound, MRI, CT, Nuclear Imaging, Mammography), Energy Sources (Light, X-rays, Ultrasound, Nuclear Magnetic Resonance...
$ 3750
Medical Image Exchange Systems Comprehensive Study by Type (Web-Based Service, Cloud-Based Solution, Mobile-Enabled Service), Application (Hospitals, Diagnostic Centers, Educational Institutes, Clini...
$ 3350